de Moraes Carlos Gustavo Vasconcelos, Facio Antonio Carlos, Costa José Humberto, Malta Roberto Freire Santiago
J Ocul Biol Dis Infor. 2009 Mar 31;2(1):40-6. doi: 10.1007/s12177-009-9020-z.
The purpose of this study was to describe the surgical outcomes and safety of intracameral bevacizumab during trabeculectomy in eyes with neovascular glaucoma. Pilot study included four eyes (four patients) with refractory neovascular glaucoma submitted to fornix-based trabeculectomy with adjunctive use of bevacizumab in the anterior chamber during the procedure. Patients were previously treated with panretinal photocoagulation as standard therapy. Variables evaluated were intraocular pressure, bleb appearance, iris neovascularization, intraoperative/postoperative complications, and visual outcomes. No intraoperative complication was observed. The mean follow-up period was 12.75 (range, 12-15 months). All eyes showed significant intraocular pressure control postoperatively. Iris neovascularization reduced significantly within 1 month after surgery. Mild anterior chamber inflammation was observed during follow-up in all eyes. No significant postoperative complication was observed, and no patient presented visual acuity deterioration. Intracameral bevacizumab may be used as an adjunctive therapy during trabeculectomy in eyes with neovascular glaucoma.
本研究的目的是描述在新生血管性青光眼患者小梁切除术中前房内注射贝伐单抗的手术效果及安全性。前瞻性研究纳入了4例（4只眼）难治性新生血管性青光眼患者，行以穹窿为基底的小梁切除术，并在术中于前房辅助使用贝伐单抗。患者此前已接受全视网膜光凝作为标准治疗。评估的变量包括眼压、滤过泡外观、虹膜新生血管、术中/术后并发症及视力预后。未观察到术中并发症。平均随访期为12.75个月（范围12 - 15个月）。所有术眼术后眼压均得到显著控制。术后1个月内虹膜新生血管显著减少。随访期间所有术眼均观察到轻度前房炎症。未观察到显著的术后并发症，且无患者出现视力下降。前房内注射贝伐单抗可作为新生血管性青光眼患者小梁切除术中的辅助治疗。
